<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883906</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0229</org_study_id>
    <nct_id>NCT03883906</nct_id>
  </id_info>
  <brief_title>Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant</brief_title>
  <official_title>Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoxworth Blood Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn more about the use of viral specific&#xD;
      T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell&#xD;
      transplant. Allogeneic means the stem cells come from another person. VSTs are cells&#xD;
      specially designed to fight viral infections that may happen after a stem cell transplant&#xD;
      (SCT).&#xD;
&#xD;
      Stem cell transplant reduces your ability to fight infections. Viral infections are a common&#xD;
      problem after transplant and can cause significant complications. Moreover, treatment of&#xD;
      viral infections is expensive and time consuming, with families often administering prolonged&#xD;
      treatments with intravenous anti-viral medications, or patients requiring prolonged&#xD;
      admissions to the hospital. The medicines can also have side effects like damage to the&#xD;
      kidneys or reduction in the blood counts, so in this study we are trying to find a way to&#xD;
      prevent these infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Toxicity</measure>
    <time_frame>up to 30 days after last VST infusion</time_frame>
    <description>Participants will be assessed for the presence of a toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute Graft-Vs-Host Disease (aGVHD)</measure>
    <time_frame>up to 30 days after last VST infusion</time_frame>
    <description>Participants will be assessed for the presence of aGVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral infection</measure>
    <time_frame>up to 30 days after last VST infusion</time_frame>
    <description>Participants will be assessed for the presence of viral infection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Allogeneic Stem Cell Transplant</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>Viral Specific T-cells (VSTs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viral Specific T-cells (VSTs)</intervention_name>
    <description>VSTs will be infused into stem cell transplant recipients</description>
    <arm_group_label>Viral Specific T-cells (VSTs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient must be at least 21 days after stem cell infusion&#xD;
&#xD;
          -  Clinical status must allow tapering of steroids to &lt; 0.5mg/kg prednisone or other&#xD;
             steroid equivalent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have developed viral infection or reactivation will be ineligible for&#xD;
             prophylactic infusions of VSTs&#xD;
&#xD;
          -  Active acute GVHD grades II-IV&#xD;
&#xD;
          -  Uncontrolled relapse of malignancy&#xD;
&#xD;
          -  Infusion of ATG or alemtuzumab within 2 weeks of VST infusion. Additionally, in&#xD;
             patients who received alemtuzumab as part of their conditioning regimen, alemtuzumab&#xD;
             levels will be collected in the second week following stem cell infusion. The level&#xD;
             must be less than, or equal to, 0.15 prior to infusion of VSTs. In patients with level&#xD;
             greater than 0.15, alemtuzumab levels can be checked serially until a level â‰¤ 0.15 is&#xD;
             obtained. They would become eligible for prophylactic VST infusion at that point if&#xD;
             there is still no evidence of viral infection at that time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Grimley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 12, 2021</submitted>
    <returned>November 9, 2021</returned>
    <submitted>November 9, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

